Title:
TRIPHASIC CONTRACEPTIVE METHOD AND KIT COMPRISING A COMBINATION OF A PROGESTIN AND ESTROGEN
Document Type and Number:
WIPO Patent Application WO1998004246
Kind Code:
A3
Abstract:
This invention provides a method of contraception which comprises administering to a female of child bearing age for 23-25 consecutive days: a first phase combination of a progestin at a daily dosage of 40-500 mu g trimegestone, 250 mu g - 4 mg dienogest, or 250 mu g - 4 mg mu g drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 mu g ethinyl estradiol for 3-8 days beginning on day 1 of the menstrual cycle, wherein the same dosage of the progestin and estrogen combination is administered in each of the 3-8 days; a second phase combination of a progestin at a daily dosage of 40-500 mu g trimegestone, 250 mu g - 4 mg dienogest, or 250 mu g - 4 mg mu g drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 mu g ethinyl estradiol, for 4-15 days beginning on the day immediately following the last day of administration of the first phase combination, wherein the same dosage of the progestin and estrogen combination is administered in each of the 4-15 days; a third phase combination of a progestin at a daily dosage of 40-500 mu g trimegestone, 250 mu g - 4 mg dienogest, or 250 mu g - 4 mg mu g drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 mu g ethinyl estradiol, for 4-15 days beginning on the day immediately following the last day of administration of the second phase combination, wherein the same dosage of the progestin and estrogen combination is administered in each of the 4-15 days; and an estrogen phase estrogen at a daily dosage equivalent in estrogenic activity to 5-20 mu g ethinyl estradiol, for 3-5 days beginning on the day immediately following the last day of administration of the third phase combination, wherein the same dosage of the estrogen is administered in each of the 3-5 days, provided that the daily dosage of the combination administered in the first phase is not the same as the daily dosage of the combination administered in the second phase and that the daily dosage of the combination administered in the second phase is not the same as the daily dosage of the combination administered in the third phase.
Inventors:
GAST MICHAEL JAY
Application Number:
PCT/US1997/012785
Publication Date:
September 26, 2002
Filing Date:
July 23, 1997
Export Citation:
Assignee:
AMERICAN HOME PROD (US)
International Classes:
A61K31/565; A61K31/57; A61K31/58; (IPC1-7): A61K31/565; A61K31/57; A61K31/58
Domestic Patent References:
| WO1995007081A1 | 1995-03-16 |
Foreign References:
| DE4313926A1 | 1994-11-03 |
Other References:
MEYER R.: "Adhearing to a proven kontraceptive", TW GYNEKOL., 1992, 5/4 (333-336), GERMANY, XP002046680
KUHL H.: "Current developments in hormonal contraception", GYNAKOLOGE, 1992, 25/4 (231-240), GERMANY, XP002046681
OELKERS W ET AL: "Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.", J CLIN ENDOCRINOL METAB, JUN 1995, 80 (6) P1816-21, UNITED STATES, XP002046682
CAROL W ET AL: "[Pharmacokinetics of contraceptive steroids with reference to long-term administration]", ZENTRALBL GYNAKOL, 1991, 113 (23) P1298-303, GERMANY, XP002046683
KUHL H.: "Current developments in hormonal contraception", GYNAKOLOGE, 1992, 25/4 (231-240), GERMANY, XP002046681
OELKERS W ET AL: "Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.", J CLIN ENDOCRINOL METAB, JUN 1995, 80 (6) P1816-21, UNITED STATES, XP002046682
CAROL W ET AL: "[Pharmacokinetics of contraceptive steroids with reference to long-term administration]", ZENTRALBL GYNAKOL, 1991, 113 (23) P1298-303, GERMANY, XP002046683
Download PDF:
Previous Patent: USE OF TRANSGLUTAMINASE MODULATORS TO PROMOTE WOUND HEALING
Next Patent: CELL ADHESION INHIBITORS
Next Patent: CELL ADHESION INHIBITORS